MatthewLouisHemmingMDPhD

PubMed

• 4 citations
  Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.
  Inga-Marie Schaefer, Matthew L Hemming, Meijun Z Lundberg, Matthew P Serrata, Isabel Goldaracena, Ninning Liu, Peng Yin, Joao A Paulo, Steven P Gygi, Suzanne George, J...> ;British Journal of Cancer. 2022 Nov 1
• 7 citations
  MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor.
  Matthew L Hemming, Morgan R Benson, Michael A Loycano, Justin A Anderson, Jessica L Andersen, Madeleine L Taddei, Andrei V Krivtsov, Brandon J Aubrey, Jevon A Cutler, ...> ;Cancer Discovery. 2022 Jul 6
• 5 citations
  Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
  Matthew L Hemming, Patrick Bhola, Michael A Loycano, Justin A Anderson, Madeleine L Taddei, Leona A Doyle, Elizaveta Lavrova, Jessica L Andersen, Kelly S Klega, Morgan...> ;Clinical Cancer Research. 2022 Jun 1
• 5 citations
  BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
  Michael C Zaiken, Ryan Flynn, Katelyn G Paz, Stephanie Y Rhee, Sujeong Jin, Fathima A Mohamed, Asim Saha, Govindarajan Thangavelu, Paul M C Park, Matthew L Hemming, Pe...> ;Blood. 2022 May 12
• 20 citations
  Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, ...
  Sophie Cousin, Jean-Yves Blay, Irene Braña Garcia, Johann S. de Bono, Christophe Le Tourneau, Victor Moreno, Jose Manuel Trigo, Christine L. Hann, Arun Azad, Seock-Ah ...> ;International Journal of Cancer. 2021 Nov 1
• 17 citations
  Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody–Drug Conjugate
  Iida Kenji, Amr H. Abdelhamid Ahmed, Akiko Kawano Nagatsuma, Tomoko Shibutani, Satoru Yasuda, Michiko Kitamura, Chiharu Hattori, Manabu Abe, Jun Hasegawa, Takuma Iguch...> ;Cancer Discovery. 2021 Feb 12
• 25 citations
  Unmet medical needs and future perspectives for leiomyosarcoma patients—A position paper from the national leiomyosarcoma foundation (NLMSF) and sarcoma patients euron...
  Bernd Kasper, Annie Achee, Kathrin Schuster, Roger Wilson, Gerard van Oortmerssen, Rebecca A. Gladdy, Matthew L. Hemming, Paul H. Huang, Matthew Ingham, Robin L. Jones...> ;Cancers. 2021 Feb 2
• 11 citations
  HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor.
  Matthew L. Hemming, Shannon Coy, Jia-Ren Lin, Jessica L. Andersen, Joanna Przybyl, Emanuele Mazzola, Amr H. Abdelhamid Ahmed, Matt van de Rijn, Peter K. Sorger, Scott ...> ;Clinical Cancer Research. 2021 Jan 15
• 18 citations
  Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes.
  Matthew L. Hemming, Changyu Fan, Chandrajit P. Raut, George D. Demetri, Scott A. Armstrong, Ewa Sicinska, Suzanne George> ;Molecular Cancer Research. 2020 Jan 1
• 26 citations
  Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1.
  Matthew L. Hemming, Michael J. Nathenson, Jia-Ren Lin, Shaolin Mei, Ziming Du, Karan Malik, Adrián Mariño-Enríquez, Jyothi P. Jagannathan, Peter K. Sorger, Monica M. B...> ;JCO Precision Oncology. 2020 Feb 14
• Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.
  William A Flavahan, Yotam Drier, Sarah E Johnstone, Matthew L Hemming, Daniel R Tarjan, Esmat Hegazi, Sarah J Shareef, Nauman M Javed, Chandrajit P Raut, Benjamin K Es...> ;Nature. 2019 Nov 1
• Altered chromosomal topology drives oncogenic programs in SDH-deficient GIST.
  Flavahan, W. A., Drier, Y., Johnstone, S. E., Hemming, M. L., Tarjan, D. R., Hegazi, E., Shareef, S. J., Javed, N. M., Raut, C. P., Eschle, B. K., Gokhale, P. C., Horn...> ;Nature. 2019 Oct 17
• 14 citations
  Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
  Matthew L. Hemming, Matthew A. Lawlor, Jessica L. Andersen, Timothy Hagan, Otari Chipashvili, Thomas G. Scott, Chandrajit P. Raut, Ewa Sicinska, Scott A. Armstrong, Ge...> ;Cancer Research. 2019 Mar 1
• 33 citations
  Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease
  Matthew L. Hemming, Kelly Klega, Justin Rhoades, Gavin Ha, Kate E Acker, Jessica L. Andersen, Edwin Thai, Anwesha Nag, Aaron R. Thorner, Chandrajit P. Raut, Suzanne Ge...> ;JCO Precision Oncology. 2019 Jan 24
• 118 citations
  Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
  Gerard L. Brien, David Remillard, Junwei Shi, Matthew L. Hemming, Jonathon Chabon, Kieran Wynne, Eugene T. Dillon, Gerard Cagney, Guido van Mierlo, Marijke P. Baltisse...> ;Elife. 2018 Nov 15
• 26 citations
  Translational insights into gastrointestinal stromal tumor and current clinical advances
  Matthew L. Hemming, Michael Heinrich, Sebastian Bauer, Suzanne George> ;Annals of Oncology. 2018 Oct 1
• 18 citations
  Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.
  Matthew L. Hemming, Matthew A. Lawlor, Rhamy Zeid, Tom Lesluyes, Jonathan A. Fletcher, Chandrajit P. Raut, Ewa Sicinska, Frédéric Chibon, Scott A. Armstrong, George D....> ;Proceedings of the National Academy of Sciences of the United States of America. 2018 Jun 19
• 26 citations
  YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.
  Matthew L. Hemming, Andrew J. Wagner, Marisa R. Nucci, Sarah Chiang, Lu Wang, Martee L. Hensley, Suzanne George> ;Gynecologic Oncology. 2017 Jun 1
• 144 citations
  Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics
  Matthew L. Hemming, Joshua E. Elias, Steven P. Gygi, Dennis J. Selkoe> ;Plos One. 2009 Dec 29
• 129 citations
  Proteomic Profiling of γ-Secretase Substrates and Mapping of Substrate Requirements
  Matthew L. Hemming, Joshua E. Elias, Steven P. Gygi, Dennis J. Selkoe> ;Plos Biology. 2008 Oct 21
• 96 citations
  Reducing Amyloid Plaque Burden via Ex Vivo Gene Delivery of an Aβ-Degrading Protease: A Novel Therapeutic Approach to Alzheimer Disease
  Matthew L. Hemming, Michaela Patterson, Casper Reske-Nielsen, Ling Lin, Ole Isacson, Dennis J. Selkoe> ;Plos Medicine. 2007 Aug 28
• 95 citations
  Effects of Prolonged Angiotensin-converting Enzyme Inhibitor Treatment on Amyloid β-Protein Metabolism in Mouse Models of Alzheimer Disease
  Matthew L. Hemming, Dennis J. Selkoe, Wesley Farris> ;Neurobiology of Disease. 2007 Apr 1
• 242 citations
  Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor
  Matthew L. Hemming, Dennis J. Selkoe> ;The Journal of Biological Chemistry. 2005 Nov 11
• 71 citations
  Alternative Splicing of Human Insulin-Degrading Enzyme Yields a Novel Isoform with a Decreased Ability To Degrade Insulin and Amyloid β-Protein†
  Wesley Farris, Malcolm A. Leissring, Matthew L. Hemming, and Alice Y. Chang, Dennis J. Selkoe> ;Biochemistry. 2005 May 3
• 135 citations
  Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity.
  Christopher J. Winrow, Matthew L. Hemming, Duane M. Allen, Gary B. Quistad, John E. Casida, Carrolee Barlow> ;Nature Genetics. 2003 Mar 17
• Join now to see all

Journal Articles

• Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical Advances  
  M C Heinrich, S George, M L Hemming, Annals of Oncology

Lectures

• Identification of leiomyosarcoma circulating tumor DNA through ultra-low passage whole genome sequencing and correlation with tumor burden: A pilot experience. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018